Infusion-related reactions may occur during or after the administration which include bronchospasm, flushing, hypotension, anaphylactic shock, or cardiac arrest. Olaratumab may cause embryo-fetal toxicity based on animal data and its mechanism of action. Other reported adverse effects include neutropenia, leukopenia, anemia, nausea and musculoskeletal pain.
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-? with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Olaratumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Olaratumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Olaratumab. |
| Estrone | Estrone may increase the thrombogenic activities of Olaratumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Olaratumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Olaratumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Olaratumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Olaratumab. |
| Estriol | Estriol may increase the thrombogenic activities of Olaratumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Olaratumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Olaratumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Olaratumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Olaratumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Olaratumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Olaratumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Olaratumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Olaratumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Olaratumab. |
| Equol | Equol may increase the thrombogenic activities of Olaratumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Olaratumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Olaratumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Olaratumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Olaratumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Olaratumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Olaratumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Olaratumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Olaratumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Olaratumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Olaratumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Olaratumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Olaratumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Olaratumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Olaratumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Olaratumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Olaratumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaratumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olaratumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Olaratumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Olaratumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Olaratumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Olaratumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Olaratumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olaratumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaratumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Olaratumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaratumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Olaratumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Olaratumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olaratumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Olaratumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Olaratumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Olaratumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olaratumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olaratumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Olaratumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Olaratumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Olaratumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Olaratumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Olaratumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Olaratumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Olaratumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Olaratumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Olaratumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Olaratumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Olaratumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Olaratumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Olaratumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Olaratumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Olaratumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Olaratumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Olaratumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Olaratumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Olaratumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Olaratumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Olaratumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Olaratumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Olaratumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Olaratumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Olaratumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Olaratumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Olaratumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Olaratumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Olaratumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Olaratumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Olaratumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Olaratumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Olaratumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Olaratumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Olaratumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Olaratumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Olaratumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Olaratumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Olaratumab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Olaratumab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Olaratumab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Canakinumab. |